Abstract Background Small interfering RNA (siRNA) is utilized as a potent agent for cancer
therapy through regulating the expression of genes associated with tumors. While the widely …

As a potent therapeutic agent, small interfering RNA (siRNA) has been exploited to silence
critical genes involved in tumor initiation and progression. However, development of a …

The tumor microenvironment is a very complex and dynamic ecosystem. Although a variety
of pH-responsive peptides have been reported to deliver nucleic acid drugs for cancer …

Cancer cells can develop in several ways to escape from death induced by
chemotherapeutic agents, thereby weakening the anti-tumor efficacy of single-target …

Cancer remains a major killer and a leading cause of death in the world; thus, a growing
number of new treatments have been focused on cancer therapy over the past few decades …

Chemoimmunotherapy can synergistically enhance the therapeutic effects and decrease the
side effects by a combined method. However, the effective targeted codelivery of various …

Introduction Drug delivery systems (DDSs) based on liposomes are potential tools to
minimize the side effects and substantially enhance the therapeutic efficacy of …

Mitochondria serve as both “energy factories” and “suicide weapon stores” of cells. Targeted
delivery of cytotoxic drugs to the mitochondria of tumor cells and tumor vascular cells is a …

The inherent features of small interfering RNA (siRNA), including a relatively high molecular
weight, negative charge, and hydrophilic nature, lead to the widespread use of cationic …

The combination of chemotherapeutic drug camptothecin (CPT) and siPlk1 could prohibit
cancer development with combined effects. To ensure the two drugs could be …